# Stoke Therapeutics Inc. (STOK) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $29.81, market value $1.9 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Stoke Therapeutics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 69.7×**. Each dollar of revenue is priced at 69.7×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 5.4×**. The shares trade at 5.4× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -9.4%** (5-yr avg -13.1%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -809.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -3.7%**. The company reported a net loss over the last twelve months.
- **Return on equity: -2.0%**. Return on equity is negative because earnings are negative.
- **Return on assets: -49.7%**. Each dollar of assets produces -49.7% of profit.

## Growth
- **Revenue growth (1 yr): 404.5%** (3-yr 145.9%/yr). Revenue grew 404.5% over the last year.
- **EPS growth (1 yr): 92.7%**. Earnings per share rose 92.7%, slower than revenue, so margins compressed.

## Financial health
- **Current ratio: 5.28** (quick 5.28). Current assets cover the next year's liabilities 5.28 times.
- **Altman Z-score: 19.66**. A Z-score of 19.66 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Stoke Therapeutics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Stoke Therapeutics Inc.; the consensus is strong_buy, with an average price target of $46.46 (+56% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 51.9%** (YTD -6.1%, 3-mo -0.7%). The shares are up 51.9% over twelve months including dividends.
- **From 52-week high: -25.9%** (46.7% above the low). Trading 26% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 40**. An RSI of 40 is neutral.
- **Beta (1 yr): 0.87** (volatility 59%). Beta of 0.87 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=STOK · Page: https://foliofundamentals.com/stocks/stok

Not investment advice.